Selleck products have been cited in
over 130,000 studies

Selleck製品は、NatureやScience等の権威ある科学雑誌に掲載された論文中で数多く使用されています

16名のノーベル賞受賞者が52報の論文においてセレック製品を使用

Katalin Karikó

Won the Nobel Prize in Physiology or Medicine in 2023


David Julius

Won the Nobel Prize in Physiology or Medicine in 2021


Michael Houghton

Won the Nobel Prize in Physiology or Medicine in 2020


Peter J. Ratcliffe

Won the Nobel Prize in Physiology or Medicine in 2019


Gregg L. Semenza

Won the Nobel Prize in Physiology or Medicine in 2019


James P. Allison

Won the Nobel Prize in Physiology or Medicine in 2018


Michael Rosbash

Won the Nobel Prize in Physiology or Medicine in 2017


Eric Richard Kandel

Won the Nobel Prize in Physiology or Medicine in 2000


Brian K. Kobilka

Won the Nobel Prize in Chemistry in 2012


Robert Lefkowitz

Won the Nobel Prize in Chemistry in 2012


Aaron Ciechanover

Won the Nobel Prize in Chemistry in 2004


化合物ライブラリー

FDA-approved Drug Library


3043種類の承認済み薬剤コレクションです

FDA-approved & Passed Phase I Drug Library


世界中で販売されている、または第1相臨床試験を通過した3456種類の薬剤を集めた化合物コレクション

Preclinical/Clinical Compound Library


世界中で販売されている、または第1相臨床試験を通過した3293種類の薬剤を集めた化合物コレクション

Bioactive Compound Library-I


9574種類の生理活性化合物コレクションです

Bioactive Compound Library-II


5076種類の生理活性化合物コレクションです

Kinase Inhibitor Library


1889種類のキナーゼ阻害剤コレクションです

Express-Pick Library


異なるコア構造の多様性を特徴とする2895化合物のユニークなコレクションです

Natural Product Library


3020種類の天然化合物コレクションです

Human Endogenous Metabolite Compound Library


835種類のヒト内因性代謝物コレクションです

Alkaloid Compound Library


433種類のアルカロイド化合物コレクションです

新製品

G150


G150 is a potent and highly selective human cyclic GMP-AMP synthase (h-cGAS) inhibitor with IC50 of 10.2 nM.

TH5487


TH5487 is a selective active-site inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1) with IC50 of 342 nM.

KGA-2727


KGA-2727 is a potent, selective, high-affinity inhibitor of sodium glucose cotransporter 1 (SGLT1) with Ki of 97.4 nM and 43.5 nM for human SGLT1 and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 exhibits antidiabetic efficacy in rodent models.

Mizagliflozin


Mizagliflozin is a novel, potent, selective sodium glucose co-transporter 1 (SGLT1) inhibitor with Ki of 27 nM for human SGLT1. The selectivity ratio (Ki value for human SGLT2/Ki value for human SGLT1) of mizagliflozin is 303. Mizagliflozin shows the potential use for the amelioration of chronic constipation.

Guadecitabine (SGI-110)


Guadecitabine (SGI-110) is a next-generation hypomethylating agent whose active metabolite decitabine has a longer in-vivo exposure time than intravenous decitabine.

CM272


CM-272 is a novel first-in-class dual reversible inhibitor of G9a (GLP) and DNMTs with IC50 of 8 nM, 382 nM, 85 nM, 1200 nM, 2 nM for G9a, DNMT1, DNMT3A, DNMT3B, GLP, respectively. CM-272 prolongs survival in in vivo models of haematological malignancies by at least in part inducing immunogenic cell death.

Visomitin (SKQ1)


INT-777 (S-EMCA) is a novel potent and selective TGR5 agonist with EC50 values of 0.18 μM, 3.9 μM and 1.45 μM for WT TGR5, TGR5(N76A) and TGR5(Y89F) respectively.

BAY1125976


BAY 1125976 is a selective allosteric AKT1/2 inhibitor,exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. BAY1125976 inhibits the activity of AKT1 (IC50 = 5.2 nM at 10 µM ATP and 44 nM at 2 mM ATP) and AKT2 (IC50 = 18 nM at 10 µM ATP and 36 nM at 2 mM ATP) very potently.Whereas BAY1125976 is almost inactive on AKT3 (IC50 = 427 nM at 10 µM ATP).

Tags: kinase inhibitors, tyrosine kinase inhibitors, enzyme inhibitors, protein inhibitors, proteins kinase inhibitors, small molecules, phosphatase inhibitors